3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Pathologic Complete Response
1
Neoplasms
1
Hemangiosarcoma
1
Breast Neoplasms
1
Interventions
Specimen Handling
449
Magnetic Resonance Spectroscopy
344
pembrolizumab
296
Biopsy
247
Carboplatin
235
Cisplatin
198
Cyclophosphamide
190
Paclitaxel
167
Nivolumab
158
Gemcitabine
154
Bevacizumab
125
Radiotherapy
122
Dexamethasone
115
fludarabine
102
Pemetrexed
102
Fluorouracil
96
Doxorubicin
92
venetoclax
91
durvalumab
91
Radiation
91
Docetaxel
91
atezolizumab
90
Oxaliplatin
89
Rituximab
88
Leucovorin
82
Capecitabine
78
Prednisone
77
Lenalidomide
71
Etoposide
69
X-Rays
67
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
SGN-LIV1A
×
30 days
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled